

## *Division of Signal Transduction Therapy*

### **Standard Operating Procedure**

#### **Preparation of ABIN2 D309N L327P [1 - 429]**

**Enzyme description:-** ABIN1 D309N L327P [1 – 429]

**Clone number:-** DU 8640

**Source:-** Recombinant

**Expression system:-** *E.coli*

**Tag:-** N-terminal GST

**Purification method:-** GSH Sepharose

**Calculated molecular mass:-**

Monoisotopic 75, 497.12 daltons

Average Mass 75, 534.75 daltons

[cysteines reduced, methionines have not been oxidised]

**Theoretical pI:-** 6.00

**Purity:-** >80 %

**Enzyme storage buffer:-**

50 mM Tris-HCl pH 7.5, 270 mM Sucrose, 150 mM NaCl, 0.1 mM EGTA,  
0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 1 mM benzamidine, 0.2 mM PMSF

**Storage temperature:-** -70 °C

*Division of Signal Transduction Therapy*

**Clone Data Sheet**

**ABIN2 D309N L327P [1 – 429]**

<b><u>Protein</u></b>	ABIN2 D309N L327P [1 – 429]
<b><u>Clone number</u></b>	DU 8640
<b><u>Species</u></b>	Human
<b><u>Accession number</u></b>	NM_024309.3
<b><u>Tags</u></b>	N-terminal GST
<b><u>Bacterially expressed protein</u></b>	<p>MSPILGYWKIKGLVQPTRLLEYLEEKYEHLIERDEGDKWRNKKFELG LEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAIEISMLEGA VLDIRYGVSR IAYSKDFETLKVDFLSKLP EMLKMFEDRLCHKTYLNGDH VTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSS KYIAWPLQGWQATFGGGDHPKSDLEVL FQGPLGSMSRDPGSGGWEEAP <b>RAAAALCTLYHEAGQRLRRLQDQLAARDAL IARLRARLAALEGDAAPSL</b> <b>VDALLEQVARFREQLRRQEGGAAEAQMRQEI ERLTERLEEKEREMOQLL</b> <b>SQPQHEREKEVVLLRRSMAEGERARAASDVLCSRSLANETHQLRRTL TAT</b> <b>AHMCQH LAKCLDERQHAQRNVGERSPDQSEHTDGH TSVQSVIEKLQ EEN</b> <b>RLLKQKVTHVEDLN AKWQRYNASRDEYVRGLHAQLRGLQIPHEPELMRK</b> <b>EISRLNRQLEEKINDCAEVKQELAA SRTARDAALERVQMLEQQILAYKD</b> <b>NFMSEADRERAQSRIQEP EEKVASLLHQVSWRQDSREPDAGRIHAGSK</b> <b>TAKYLAADALELMVPGGWRPGTGSQQPEPPAEGGHPGAVQRGQGDLOCP</b> <b>HCLQCF SDEQGEELLRHVAECCQ</b></p>
<b><u>Native sequence</u></b>	<p>Amino acids M1 – Q429 (end) of human ABIN2. Residue M232 of the fusion protein is equivalent to M1 of the native enzyme. The GST tag is located at residues 1 – 220. The protein has a D309N and an L327P mutation. Residue D309 is equivalent to residue N540 of the fusion protein and residue L327 is equivalent to P558.</p>
<b><u>Protease cleavage</u></b>	PreScission (LEVL FQGP) residues 221 - 228
<b><u>Cloning sites</u></b>	<i>Bam</i> H1 and <i>Not</i> 1 sites of pGEX6P-1

## *Division of Signal Transduction Therapy*

### Nucleotide Sequence Of Insert

ggatccATGTCCCGGGACCCGGGGTCTGGGCGGCTGGGAGGAGGCCCCGC  
GCGCAGCTGCCGCGCTCTGCACCCTGTACCACGAGGCCGGACAGCGGCT  
GCGCCGCTGCAGGACCAGCTCGCTGCCCGCGACGCCCTCATCGCTCGC  
CTCCGCGCCCGCCTGGCCGCGCTGGAGGGGGACGCCGCGCCGTCCCTAG  
TGGACGCGCTGCTGGAGCAGGTTGCGCGCTTCCGGGAGCAGCTGCGAAG  
GCAGGAGGGCGGCGCCGCGAGGCCAGATGCGCCAGGAAATTGAGAGG  
CTGACTGAGCGACTAGAAGAAAAAGAGAGGGAGATGCAGCAGCTGCTGA  
GCCAGCCCCAACACGAGCGAGAGAAGGAAGTCGTCCTGCTACGGAGGAG  
CATGGCAGAAGGGGAGCGCGCCCGGGCCGCCAGTGACGTCCTGTGCCGC  
TCCTTGGCCAACGAGACCCATCAGCTGCGGAGGACGCTGACCGCCACCG  
CCCACATGTGTCAGCATCTGGCCAAGTGTCTGGATGAACGACAGCATGC  
ACAAAGGAATGTGGGGGAGAGAAGTCCTGACCAGTCGGAACACACAGAT  
GGGCACACCTCTGTCCAGAGTGTATTGAGAAGTTGCAGGAAGAAAATC  
GACTGTTAAAACAGAAGGTGACTCACGTTGAAGACCTCAATGCCAAGTG  
GCAGCGCTACAACGCCAGCAGGGACGAATACGTGAGGGGGCTCCATGCG  
CAGCTCAGGGGGCTGCAGATCCCCACGAGCCCGAGCTGATGAGGAAGG  
AGATCTCCCGGCTCAACAGACAGTTGGAAGAGAAAATAAATGACTGTGC  
CGAAGTGAAGCAGGAGCTGGCGGCCTCCAGGACGGCCCGGGATGCTGCG  
TTGGAGCGGGTGCAGATGCTGGAACAGCAGATTCTCGCTTACAAGGATA  
ACTTCATGTCAGAAAGGGCCGATCGGGAACGGGCTCAAAGTAGGATTCA  
AGAACCGGAGGAAAAGGTCGCCTCTTTGCTGCACCAGGTGTCCTGGAGA  
CAGGATTCTCGAGAGCCAGACGCCGGCCGGATTACGCTGGGAGCAAAA  
CTGCCAAGTATTTGGCCGCCGACGCATTAGAGCTTATGGTGCTGGTGG  
CTGGAGGCCTGGGACTGGGTCCCAGCAGCCAGAACCCCTGCAGAGGGC  
GGGCATCCTGGCGCGGTCCAGAGAGGCCAGGGGGACCTTCAGTGCCCTC  
ACTGCCTGCAGTGCTTCAGTGACGAGCAAGGGGAAGAGCTCCTCAGGCA  
TGTGGCCGAGTGCTGCCAGtgagcggccgc